mRNA vaccines can be used for broader infectious diseases prevention and cancer therapy
Messenger RNA (mRNA) vaccine technology, decades in development as a therapy for cancer and for prevention of infectious diseases but not yet realising a licensed product,1 was rapidly implemented to accelerate the creation of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) vaccines. Yet their spectacular success against SARS‐CoV‐2 provides just a glimpse of their full potential. This article describes how mRNA vaccines are made and how they work, and their potential for further infectious disease prevention and cancer therapy.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.